Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Sponsor
Methodist Health System
Study ID
NCT06222437
Phase
PHASE1
Status
Withdrawn

Conditions

  • Polycystic Ovary Syndrome

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    effectiveness of semaglutide in PCOS

Study Details

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Key Dates

First listed
Jan 24, 2024
Start date
Feb 28, 2026
Status verified
Jan 2026
Primary completion
Feb 28, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Protocol group
    PCOS women in the age 18 to 45 years

Primary Outcome Measure

Number of appropriate weekly dose [ Time Frame: 4 weeks ]

Related Studies